Appendix/Supplement (Billette et al.)

e-Tables

Table e-1. Univariate ANOVAs predicting ROI activity by clinical groups and additional covariates

Model 0a Diagnosis Group N=486 Hippocampus Precuneus 31,154 99,889 90,929 3 10,385 13,296 2,567 2,786 0,040 0,017 7,700 8,358 6,71 6,32 Model 0b Diagnosis Group M=224 (CSF) N=224 (CSF)	Factor/Covariat e	ROI	Sum of Squares	df	Mean square	F	Sig.	Partial Eta2	Decentere d Parameter	power
Diagnosis Group Entorhinal Ctx. 31,154 3 10,385 2,567 .054 .016 7,700 .632 Group 99,899 3 13,296 2,786 .040 .017 8,358 .671 Diagnosis Group N=224 (CSF) Entorhinal Ctx. 40,545 3 13,515 3,443 .018 .047 10,329 .767 Hippocampus 98,042 3 12,681 2,566 .056 .035 7,697 .626 Precuneus 93,468 3 31,156 4,933 .002 .066 14,799 .908 Model 1 N=476 Entorhinal Ctx. 32,340 3 10,780 .626 .050 .017 .7879 .643 Group Precuneus 72,680 3 24,227 .3542 .016 .7,328 .608 APOE4 status Hippocampus 9,189 1 9,189 .169 .004 1.899 .289 Diagnosis Group Entorhinal Ctx.	Model 0a	N=486								
Diagnosis Group Hippocampus 39,889 3 13,296 2,786 ,040 ,017 8,358 ,671 Model Ob Diagnosis Group N=224 (CSF) Impocampus 30,310 4,313 ,005 ,027 12,939 ,866 Model Ob Group N=224 (CSF) Impocampus 38,042 3 13,515 3,443 ,018 ,047 10,329 ,767 Model I N=476 Impocampus 38,042 3 11,821 2,666 ,056 ,035 7,697 ,663 Diagnosis Group Entorhinal Ctx. 32,468 3 11,821 2,443 ,064 ,016 7,328 ,663 Diagnosis Group Precuneus 72,680 3 24,227 3,542 ,015 ,023 10,626 ,732 APOE4 status Hippocampus 9,189 1 9,189 1,899 ,690 ,004 1,899 ,280 Precuneus 5,33 1 ,533 ,078 ,700 ,001 ,470			31,154	3	10.385	2,567	.054	.016	7,700	.632
Group Precuneus 90,929 3 30,310 4,313 ,005 ,027 12,939 ,866 Model 0b Group N=224 (CSF) Hippocampus A 30,310 4,313 ,005 ,027 12,939 ,866 Group Entorhinal Ctx. 40,545 3 13,515 3,443 ,018 ,047 10,329 ,767 Model 1 N=476 State 31,156 4,933 ,002 ,066 14,799 ,908 Model 1 N=476 Entorhinal Ctx. 32,3463 3 10,780 2,626 ,050 ,017 7,879 ,643 Diagnosis Group Entorhinal Ctx. 1,929 1 1,929 ,470 ,493 ,001 ,470 ,105 APOE4 status Hippocampus 9,189 1 9,189 1,899 ,807 ,000 ,001 ,470 ,105 Diagnosis Group Entorhinal Ctx. 39,618 3 13,206 3,365 ,002 ,006 ,01,999 ,28	•									
Model 0b Diagnosis Group N=224 (CSF) Entorhinal Ctx. 40.545 3 13.515 3.443 .018 .047 10.329 .767 Model 1 N=476 93.468 3 11.56 4.933 .002 .066 14.799 .908 Model 1 N=476 Entorhinal Ctx. 32.340 3 10.780 2.626 .050 .017 7.879 .643 Diagnosis Group Precuneus 72.680 3 24.227 .3542 .016 7.328 .608 APOE4 status Hippocampus 9.189 1 9.199 .470 .493 .001 .470 .105 Model 2a N=224 .533 1 3.13.50 .002 .046 10.096 .053 Model 2a N=224 .010 .029 .6267 .529 .002 .046 10.096 .057 Model 2b N=224 .0451 .3 .13.206 .3365 .002 .046 .14.858 .909 CS	Group	• •								
Diagnosis Group Entorhinal Ctx. 40,545 3 13,515 3,443 0.18 0,047 10,329 ,767 Hippocampus Precuneus 93,468 3 12,681 2,566 0.056 0.355 7,697 626 Diagnosis Group N=476 N 3 10,780 2,626 0.50 0.017 7,879 ,643 Diagnosis Group Entorhinal Ctx. 32,340 3 10,780 2,626 0.50 0.017 7,879 ,643 APOE4 status Hippocampus 72,680 3 24,227 3,542 0.01 ,470 ,105 Precuneus ,533 1 533 0.78 ,780 0.00 ,078 ,059 Model 2a N=224 N=416 ,4183 1,066 ,303 0.005 1,4858 ,909 CSF A842/40 Entorhinal Ctx. <td>Model 0b</td> <td></td> <td></td> <td></td> <td></td> <td>,</td> <td>,</td> <td>, -</td> <td>,</td> <td>,</td>	Model 0b					,	,	, -	,	,
Group Entominal CX. 40,545 3 13,515 3,443 .047 10.329 .767 Model 1 N=476 I State 12,681 2,566 .056 .053 .7697 .626 Diagnosis Group Entorninal Ctx. 32,340 3 11,561 4,433 .002 .066 14,799 .908 Model 1 N=476 I I .24,227 .3,542 .015 .023 10,626 .7879 .643 Group Entorninal Ctx. 1,929 1 1,929 .470 .433 .001 .470 .1058 APOE4 status Hippocampus 9,189 1 9,189 1,899 .168 .004 1,899 .280 Model 2a N=224 I I .31,350 .4953 .002 .004 1,899 .280 Model 2b N=224 I I .4183 I .4183 .026 .3065 .0020 .066 .14,858 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>										
Precuneus 93,468 3 31,156 4,933 ,002 ,066 14,799 ,908 Model 1 Group N=476 Entorhinal Ctx. 32,3403 3 10,780 2,660 ,050 ,017 7,879 ,643 Bippocampus 35,463 3 11,821 2,443 ,064 ,016 7,328 ,608 APOE4 status Hippocampus 9,189 1 9,189 1,829 ,470 ,493 ,001 ,470 ,105 Model 2a N=224 Precuneus ,533 1 ,533 ,078 ,780 ,000 ,078 ,659 Model 2a N=224 N=224 N		Entorninal Ctx.	40,545	3	13,515	3,443	,018	,047	10,329	,767
Precuneus 93,468 3 31,156 4,933 ,002 ,066 14,799 ,908 Model 1 Group N=476 Entorhinal Ctx. 32,3403 3 10,780 2,660 ,050 ,017 7,879 ,643 Bippocampus 35,463 3 11,821 2,443 ,064 ,016 7,328 ,608 APOE4 status Hippocampus 9,189 1 9,189 1,829 ,470 ,493 ,001 ,470 ,105 Model 2a N=224 Precuneus ,533 1 ,533 ,078 ,780 ,000 ,078 ,659 Model 2a N=224 N=224 N		Hippocampus	38,042	3	12,681	2,566	,056	,035	7,697	,626
Model 1 N=476 N=424 N=476 N=426 N=476 <		Precuneus		3	31,156		.002			
Diagnosis Group Entorhinal Ctx. 32,340 3 10,780 2,262 ,050 ,017 7,879 ,643 Broup Precuneus 72,680 3 11,821 2,443 ,064 ,016 7,328 ,608 APOE4 status Entorhinal Ctx. 1,929 1 1,929 ,470 ,493 ,001 ,470 ,105 APOE4 status Hippocampus 9,189 1 9,189 1,899 ,169 ,004 1,899 ,280 Model 2a N=224 J J 3 1,3206 3,365 ,000 ,046 10,096 ,757 Hippocampus 31,100 3 10,367 2,089 ,103 ,029 6,267 ,529 Precuneus 94,051 3 31,350 4,953 ,002 ,066 14,858 ,909 CSF AB42/40 Entorhinal Ctx. 4,183 1 4,183 1,646 ,402 ,003 ,543 ,114 Diagnosis Group	Model 1	N=476	,	-		.,	,	,	,	,
Diagnosis Group Hippocampus Precuneus 35,463 3 11,821 2,443 ,064 ,016 7,328 ,608 APOE4 status Precuneus 72,680 3 24,227 3,542 ,015 ,023 10,626 ,785 APOE4 status Hippocampus 9,189 1 9,189 1,899 ,169 ,004 1,899 ,280 Model 2a N=224 Interthinal Ctx. 39,618 3 13,206 3,365 ,020 ,046 10,096 ,757 Hippocampus 31,100 3 10,367 2,089 ,103 ,029 6,267 ,529 Precuneus 94,051 3 31,350 4,953 ,002 ,046 14,858 ,909 CSF AB42/40 Entorhinal Ctx. 4,183 1 4,183 1,066 ,303 ,005 1,066 ,177 Hippocampus 31,413 3 10,478 2,112 ,000 ,6335 ,534 Diagnosis Group Entorhinal			32.340	3	10.780	2.626	.050	.017	7.879	.643
Group Precuneus 72,680 3 24,227 3,542 ,015 .023 10,626 ,785 APOE4 status Entorhinal Ctx. 1,929 1 1,929 ,470 ,493 ,001 ,470 ,105 APOE4 status Hippocampus 9,189 1 9,189 1,899 ,169 ,004 1,899 ,280 Model 2a N=224 . . ,533 1 ,533 ,078 ,780 ,000 ,078 ,559 Model 2a N=224 ,31,100 3 10,367 2,089 ,004 10,096 ,757 Hippocampus 3,1100 3 13,510 4,953 ,002 ,066 ,14,858 ,909 CSF AB42/40 Entorhinal Ctx. 4,183 1 4,183 1,066 ,303 ,005 1,066 ,777 Model 2b N=224 . N=224<	•									,
APOE4 status Entorhinal Ctx. 1,929 1 1,929 470 493 ,001 ,470 ,105 Model 2a Diagnosis Group m=224 state s	Group									
APOE4 status Hippocampus Precuneus 9,189 1 9,189 1,899 ,169 ,004 1,899 ,280 Model 2a N=224 Entorhinal Ctx. 39,618 3 13,206 3,365 ,020 ,046 10,096 ,757 Hippocampus 31,100 3 10,367 2,089 ,103 ,022 ,066 14,858 ,909 CSF AB42/40 Entorhinal Ctx. 4,183 1 4,183 1,066 ,303 ,005 1,066 ,177 Hippocampus ,740 1 ,740 1 ,413 ,462 ,003 ,543 ,114 Model 2b N=224 Entorhinal Ctx. 38,856 3 12,952 3,291 ,002 ,045 9,874 ,746 Diagnosis Group Entorhinal Ctx. 1,846 1 1.846 1,895 ,169 ,002 ,045 9,874 ,746 Diagnosis Group Entorhinal Ctx. 1,846 1 1.846 1,805 ,162										
Precuneus ,533 1 ,533 ,533 ,780 ,000 ,078 ,059 Model 2a Diagnosis Group Entorhinal Ctx. 39,618 3 13,206 3,365 ,020 ,046 10,096 ,757 Precuneus 94,051 3 13,306 4,953 ,002 ,046 14,858 ,909 CSF AB42/40 Entorhinal Ctx. 4,183 1 4,183 1,066 ,303 ,005 1,066 ,177 Model 2b N=224 Entorhinal Ctx. 4,183 1 4,183 1,066 ,303 ,005 1,066 ,177 Model 2b N=224 Entorhinal Ctx. 38,856 3 12,952 3,291 ,022 ,045 9,874 ,746 Diagnosis Group Entorhinal Ctx. 18,846 1 1,846 ,469 ,002 ,469 ,105 CSF p-tau Entorhinal Ctx. 1,944 1 1,846 ,469 ,002 ,469 ,105 Hippocampus	APOF4 status									
Model 2a Diagnosis Group N=224 Entorhinal Ctx. 39,618 31,100 3 13,206 10,367 2,089 2,085 ,020 ,020 ,046 0,026 10,096 6,267 ,529 5,299 CSF AB42/40 Entorhinal Ctx. 4,183 1 4,183 1,066 ,005 1,066 ,177 Hippocampus 740 1 4,183 1,049 ,005 1,066 ,177 Model 2b N=224 740 1 ,740 ,740 ,740 ,740 ,022 ,045 9,874 ,746 Diagnosis Group Entorhinal Ctx. 38,856 3 12,952 3,291 ,022 ,045 9,874 ,746 Hippocampus 31,433 3 10,478 2,112 ,100 ,029 6,335 ,534 Precuneus 93,393 3 31,131 4,913 ,003 ,066 14,738 ,906 CSF p-tau Entorhinal Ctx. 1,846 1 1,845 ,469 ,404 ,002 ,469 ,105 Diagnos										
Diagnosis Group Entorhinal Ctx. 39,618 3 13,206 3,365 ,020 ,046 10,096 ,757 Precuneus 94,051 3 31,350 4,953 ,002 ,066 14,858 ,909 CSF AB42/40 Entorhinal Ctx. 4,183 1 4,183 1,066 ,303 ,005 1,066 ,177 Hippocampus ,740 1 ,740 ,149 ,700 ,001 ,149 ,067 Precuneus 3,435 1 3,435 ,543 ,462 ,003 ,543 ,114 Model 2b N=224 ,675 ,534 Precuneus 31,433 10,478 2,112 ,100 ,029 6,335 ,534 Precuneus 31,433 3 10,478 2,112 ,100 ,002 ,469 ,105 Hippocampus 3,805 1 1,806 ,162 ,688 ,001 ,152 ,669	Model 2a		,000		,000	,070	,700	,000	,070	,000
Hippocampus 31,100 3 10,367 2,089 ,103 ,029 6,267 ,529 CSF AB42/40 Entorhinal Ctx. 4,183 1 4,183 1,066 ,303 ,005 1,066 ,177 Precuneus 3,435 1 4,183 1,049 ,700 ,001 ,149 ,067 Precuneus 3,435 1 3,435 ,543 ,462 ,003 ,543 ,114 Model 2b N=224 Entorhinal Ctx. 38,856 3 12,952 3,291 ,022 ,045 9,874 ,746 Hippocampus 31,433 3 10,478 2,112 ,100 ,029 6,335 ,534 Precuneus 93,393 3 31,131 4,913 ,003 .066 14,738 906 CSF p-tau Entorhinal Ctx. 1,846 1 1,846 ,469 ,494 ,002 ,469 ,105 Diagnosis Group Hippocampus 25,836 3 8,61			39 618	З	13 206	3 365	020	046	10.096	757
Precuneus 94,051 3 31,350 4,953 ,002 .066 14,858 .909 CSF AB42/40 Entorhinal Ctx. 4,183 1 4,183 1,066 ,303 ,005 1,066 ,177 Model 2b N=224 3,435 1 3,435 ,543 ,462 ,003 ,543 ,114 Model 2b N=224 Entorhinal Ctx. 38,856 3 12,952 3,291 ,022 ,045 9,874 ,746 Diagnosis Group Entorhinal Ctx. 38,856 3 12,952 3,291 ,002 ,045 9,874 ,746 Diagnosis Group Entorhinal Ctx. 1,846 1 1,846 ,469 ,494 ,002 ,469 ,105 CSF p-tau Entorhinal Ctx. 1,846 1 1,846 ,469 ,494 ,002 ,469 ,105 Model 2c N=224 Entorhinal Ctx. 1,973 1 1,973 ,311 ,577 ,001 ,311 ,08						-	-			
CSF AB42/40 Entorhinal Ctx. 4,183 1 4,183 1,066 ,303 ,005 1,066 ,177 Hippocampus ,740 1 ,740 1 ,740 ,149 ,700 ,001 ,149 ,067 Precuneus 3,435 1 3,435 ,543 ,462 ,003 ,543 ,114 Model 2b N=224 Impocampus 31,433 10,478 2,112 ,100 ,029 6,335 ,534 Diagnosis Group Entorhinal Ctx. 1,846 1 1,846 ,469 ,494 ,002 ,469 ,105 CSF p-tau Entorhinal Ctx. 1,846 1 1,846 ,469 ,494 ,002 ,469 ,105 Model 2c N=224 Impocampus ,805 1 ,805 ,162 ,688 ,001 ,162 ,069 Precuneus 1,973 1 1,973 ,311 ,577 ,001 ,311 ,086 Diagnosis Group										
Hippocampus Precuneus ,740 3,435 1 ,740 3,435 1 ,740 3,435 ,149 5,543 ,001 462 ,149 003 ,067 5,543 Model 2b Diagnosis Group N=224 N <t< td=""><td>CSE 4842/40</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	CSE 4842/40									
Precuneus 3,435 1 3,435 ,543 ,462 ,003 ,543 ,114 Model 2b N=224 Image: Second Sec	001 A042/40									
Model 2b N=224 38,856 3 12,952 3,291 ,022 ,045 9,874 ,746 Diagnosis Group Entorhinal Ctx. 38,856 3 10,478 2,112 ,100 ,029 6,335 ,534 Precuneus 93,393 3 31,131 4,913 ,003 ,066 14,738 906 CSF p-tau Entorhinal Ctx. 1,846 1 1,805 ,162 ,688 ,001 ,162 ,069 Precuneus 1,973 1 1,973 ,311 ,577 ,001 ,311 ,086 Model 2c N=224 Entorhinal Ctx. 39,414 3 13,138 3,359 ,020 ,046 10,078 ,756 Diagnosis Group Hippocampus 25,836 3 8,612 1,745 ,159 ,024 5,235 ,452 Precuneus 93,388 3 31,129 4,906 ,003 ,066 14,719 ,906 CSF AB42/p-tau Hippocampus <td></td> <td></td> <td></td> <td></td> <td>,</td> <td></td> <td></td> <td></td> <td></td> <td></td>					,					
Diagnosis Group Entorhinal Ctx. Hippocampus 38,856 3 12,952 3,291 ,022 ,045 9,874 ,746 Hippocampus 31,433 3 10,478 2,112 ,100 ,029 6,335 ,534 Precuneus 93,393 3 31,131 4,913 ,003 ,066 14,738 ,906 CSF p-tau Entorhinal Ctx. 1,846 1 1,846 ,469 ,494 ,002 ,469 ,105 Model 2c N=224 1,973 1 1,973 ,311 ,577 ,001 ,311 ,086 Diagnosis Group Hippocampus 25,836 3 8,612 1,745 ,159 ,024 5,235 ,452 Diagnosis Group Hippocampus 25,836 3 8,612 1,745 ,159 ,024 5,235 ,452 Precuneus 93,388 3 31,129 4,906 ,003 ,066 14,719 ,906 CSF AB42/p-tau Hippocampus	Model 2b		0,400		0,400	,040	,402	,000	,040	, 117
Hippocampus Precuneus 31,433 93,393 3 10,478 2,112 ,100 ,029 6,335 ,534 CSF p-tau Entorhinal Ctx. 1,846 1 1,846 ,469 ,494 ,002 ,469 ,105 CSF p-tau Entorhinal Ctx. 1,846 1 1,846 ,469 ,494 ,002 ,469 ,105 Model 2c N=224 1 ,805 ,162 ,688 ,001 ,162 ,069 Precuneus 1,973 1 1,973 ,311 ,577 ,001 ,311 ,086 Model 2c N=224 ,175 ,001 ,311 ,086 Diagnosis Group Hippocampus 25,836 3 8,612 1,745 ,159 ,024 5,235 ,452 Precuneus 93,388 3 31,129 4,906 ,003 ,066 14,719 ,906 CSF AB42/p-tau Hippocampus 6,312 1 <			38 856	3	12 952	3 291	.022	045	9 874	746
Precuneus 93,393 3 31,131 4,913 ,003 ,066 14,738 ,906 CSF p-tau Entorhinal Ctx. 1,846 1 1,846 ,469 ,494 ,002 ,469 ,105 Model 2c N=224 1 1,973 1 1,973 ,311 ,577 ,001 ,311 ,086 Diagnosis Group Hippocampus 25,836 3 8,612 1,745 ,159 ,024 5,235 ,452 Precuneus 93,388 3 31,129 4,906 ,003 ,066 14,719 ,906 CSF AB42/p-tau Hippocampus 6,312 1 6,954 1,778 ,184 ,008 1,778 ,264 CSF AB42/p-tau Hippocampus 6,312 1 6,312 1,279 ,259 ,006 1,279 ,203 Precuneus ,315 1 ,315 ,050 ,824 ,000 ,050 ,056 Model 3 N=486 Incorbinal Ctx.	Blaghoolo aroup						-			
CSF p-tau Entorhinal Ctx. 1,846 1 1,846 ,469 ,494 ,002 ,469 ,105 Hippocampus ,805 1 ,805 1 ,805 ,162 ,688 ,001 ,162 ,069 Precuneus 1,973 1 1,973 ,311 ,577 ,001 ,311 ,086 Model 2c N=224 Entorhinal Ctx. 39,414 3 13,138 3,359 ,020 ,046 10,078 ,756 Diagnosis Group Hippocampus 25,836 3 8,612 1,745 ,159 ,024 5,235 ,452 Precuneus 93,388 3 31,129 4,906 ,003 ,066 14,719 ,906 CSF AB42/p-tau Hippocampus 6,312 1 6,312 1,279 ,259 ,006 1,279 ,203 Precuneus ,315 1 ,315 ,050 ,824 ,000 ,050 ,056 Model 3 N=486										
Hippocampus Precuneus ,805 1 ,805 ,162 ,688 ,001 ,162 ,069 Model 2c N=224 1,973 1 1,973 ,311 ,577 ,001 ,311 ,086 Diagnosis Group Hippocampus 25,836 3 13,138 3,359 ,020 ,046 10,078 ,756 Diagnosis Group Hippocampus 25,836 3 8,612 1,745 ,159 ,024 5,235 ,452 Precuneus 93,388 3 31,129 4,906 ,003 ,066 14,719 ,906 CSF AB42/p-tau Entorhinal Ctx. 6,954 1 6,954 1,778 ,184 ,008 1,778 ,264 CSF AB42/p-tau Hippocampus 6,312 1 ,315 ,050 ,824 ,000 ,050 ,566 Model 3 N=486 Intorhinal Ctx. 31,271 3 10,424 2,571 ,054 ,016 7,713 ,632 Diagnosis	CSF p-tau									
Precuneus 1,973 1 1,973 ,311 ,577 ,001 ,311 ,086 Model 2c N=224 Entorhinal Ctx. 39,414 3 13,138 3,359 ,020 ,046 10,078 ,756 Diagnosis Group Hippocampus 25,836 3 8,612 1,745 ,159 ,024 5,235 ,452 Precuneus 93,388 3 31,129 4,906 ,003 ,066 14,719 ,906 CSF Aß42/p-tau Entorhinal Ctx. 6,954 1 6,954 1,778 ,184 ,008 1,778 ,264 Diagnosis Group Hippocampus 6,312 1 6,312 1,279 ,259 ,006 1,279 ,203 Precuneus ,315 1 ,315 ,050 ,824 ,000 ,050 ,056 Model 3 N=486 Entorhinal Ctx. 31,271 3 10,424 2,571 ,054 ,016 7,713 ,632 Diagnosis Group <td></td>										
Model 2c N=224 Entorhinal Ctx. 39,414 3 13,138 3,359 ,020 ,046 10,078 ,756 Diagnosis Group Hippocampus 25,836 3 8,612 1,745 ,159 ,024 5,235 ,452 Precuneus 93,388 3 31,129 4,906 ,003 ,066 14,719 ,906 CSF Aß42/p-tau Entorhinal Ctx. 6,954 1 6,954 1,778 ,184 ,008 1,778 ,264 CSF Aß42/p-tau Hippocampus 6,312 1 6,312 1,279 ,259 ,006 1,279 ,203 Precuneus ,315 1 ,315 ,050 ,824 ,000 ,050 ,056 Model 3 N=486 Entorhinal Ctx. 31,271 3 10,424 2,571 ,054 ,016 7,713 ,632 Diagnosis Group Hippocampus 36,485 3 12,162 2,543 ,056 ,016 7,628 ,627 <t< td=""><td></td><td></td><td></td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>				1						
Diagnosis Group Hippocampus Precuneus 25,836 3 8,612 1,745 ,159 ,024 5,235 ,452 Precuneus 93,388 3 31,129 4,906 ,003 ,066 14,719 ,906 CSF AB42/p-tau Entorhinal Ctx. 6,954 1 6,954 1,778 ,184 ,008 1,778 ,264 Model 3 Hippocampus 6,312 1 6,312 1,279 ,259 ,006 1,279 ,203 Precuneus ,315 1 ,315 ,050 ,824 ,000 ,050 ,056 Model 3 N=486 Impocampus 31,271 3 10,424 2,571 ,054 ,016 7,713 ,632 Diagnosis Group Hippocampus 36,485 3 12,162 2,543 ,056 ,016 7,628 ,627 Precuneus 90,855 3 30,285 4,300 ,005 ,027 12,901 ,865 Entorhinal Ctx. ,199<	Model 2c	N=224								
Precuneus 93,388 3 31,129 4,906 ,003 ,066 14,719 ,906 CSF AB42/p-tau Entorhinal Ctx. 6,954 1 6,954 1,778 ,184 ,008 1,778 ,264 CSF AB42/p-tau Hippocampus 6,312 1 6,312 1,279 ,259 ,006 1,279 ,203 Precuneus ,315 1 ,315 ,050 ,824 ,000 ,050 ,056 Model 3 N=486 Impocampus 36,485 3 12,162 2,571 ,054 ,016 7,713 ,632 Diagnosis Group Hippocampus 36,485 3 12,162 2,543 ,056 ,016 7,628 ,627 Precuneus 90,855 3 30,285 4,300 ,005 ,027 12,901 ,865 Entorhinal Ctx. ,199 1 ,199 ,049 ,825 ,000 ,049 ,056 Regional Volume Hippocampus ,033		Entorhinal Ctx.	39,414	3	13,138	3,359	,020	,046	10,078	,756
Precuneus 93,388 3 31,129 4,906 ,003 ,066 14,719 ,906 CSF AB42/p-tau Entorhinal Ctx. 6,954 1 6,954 1,778 ,184 ,008 1,778 ,264 CSF AB42/p-tau Hippocampus 6,312 1 6,312 1,279 ,259 ,006 1,279 ,203 Precuneus ,315 1 ,315 ,050 ,824 ,000 ,050 ,056 Model 3 N=486 Impocampus 36,485 3 12,162 2,571 ,054 ,016 7,713 ,632 Diagnosis Group Hippocampus 36,485 3 12,162 2,543 ,056 ,016 7,628 ,627 Precuneus 90,855 3 30,285 4,300 ,005 ,027 12,901 ,865 Entorhinal Ctx. ,199 1 ,199 ,049 ,825 ,000 ,0049 ,056 Regional Volume Hippocampus ,033	Diagnosis Group	Hippocampus	25,836	3	8,612	1,745	,159	,024	5,235	,452
Entorhinal Ctx. 6,954 1 6,954 1,778 ,184 ,008 1,778 ,264 CSF Aß42/p-tau Hippocampus 6,312 1 6,312 1,279 ,259 ,006 1,279 ,203 Precuneus ,315 1 ,315 ,050 ,824 ,000 ,050 ,056 Model 3 N=486 Impocampus 31,271 3 10,424 2,571 ,054 ,016 7,713 ,632 Diagnosis Group Hippocampus 36,485 3 12,162 2,543 ,056 ,016 7,628 ,627 Precuneus 90,855 3 30,285 4,300 ,005 ,027 12,901 ,865 Entorhinal Ctx. ,199 1 ,199 ,049 ,825 ,000 ,049 ,056 Regional Volume Hippocampus ,033 1 ,033 ,007 ,934 ,000 ,007 ,051			93,388	3	31,129	4,906			14,719	
CSF AB42/p-tau Hippocampus Precuneus 6,312 ,315 1 6,312 ,315 1,279 ,259 ,006 1,279 ,203 Model 3 N=486 I ,315 1 ,315 ,050 ,824 ,000 ,050 ,056 Model 3 N=486 I I 31,271 3 10,424 2,571 ,054 ,016 7,713 ,632 Diagnosis Group Hippocampus 36,485 3 12,162 2,543 ,056 ,016 7,628 ,627 Precuneus 90,855 3 30,285 4,300 ,005 ,027 12,901 ,865 Entorhinal Ctx. ,199 1 ,199 ,049 ,825 ,000 ,049 ,056 Regional Volume Hippocampus ,033 1 ,033 ,007 ,934 ,000 ,007 ,051				1						
Precuneus ,315 1 ,315 ,050 ,824 ,000 ,050 ,056 Model 3 N=486 Image: Constraint of the con	CSF A642/p-tau									
Model 3 N=486 Image: Second system </td <td></td>										
Entorhinal Ctx. 31,271 3 10,424 2,571 ,054 ,016 7,713 ,632 Diagnosis Group Hippocampus 36,485 3 12,162 2,543 ,056 ,016 7,628 ,627 Precuneus 90,855 3 30,285 4,300 ,005 ,027 12,901 ,865 Entorhinal Ctx. ,199 1 ,199 ,049 ,825 ,000 ,049 ,056 Regional Volume Hippocampus ,033 1 ,033 ,007 ,934 ,000 ,007 ,051	Model 3		,-·•		, •	,	,- - .	,	,	,
Diagnosis Group Hippocampus 36,485 3 12,162 2,543 ,056 ,016 7,628 ,627 Precuneus 90,855 3 30,285 4,300 ,005 ,027 12,901 ,865 Entorhinal Ctx. ,199 1 ,199 ,049 ,825 ,000 ,049 ,056 Regional Volume Hippocampus ,033 1 ,033 ,007 ,934 ,000 ,007 ,051			31,271	3	10,424	2,571	.054	.016	7,713	.632
Precuneus 90,855 3 30,285 4,300 ,005 ,027 12,901 ,865 Entorhinal Ctx. ,199 1 ,199 ,049 ,825 ,000 ,049 ,056 Regional Volume Hippocampus ,033 1 ,033 ,007 ,934 ,000 ,007 ,051	Diagnosis Group									
Entorhinal Ctx.,1991,199,049,825,000,049,056Regional VolumeHippocampus,0331,033,007,934,000,007,051	5									
Regional Volume Hippocampus ,033 1 ,033 ,007 ,934 ,000 ,007 ,051										
	Regional Volume			1						
Precuneus 000 1 COU, 1 COU, 1 COU, 000	J I	Precuneus	,003	1	,003	,000	,983	,000	,000	,050

Univariate follow-up ANOVAs predicting activity in each of the three a priori ROIs by clinical group (CN, SCD, MCI, AD dementia). Covariates in all models were age, sex, and site of the MRI scan (results not shown in Table). Model 0 is the original model in all subjects (Model 0a) and the subsample with CSF biomarkers (Model 0b). Model 1, 2a-c and 3 were additionally adjusted for APOE4 genotype, AD pathology or ROI-specific gray matter volume (adjusted by intracranial volume). Significant effects are highlighted in bold. The effect of clinical group on precuneus activity was significant when controlling for APOE4 genotype, CSF markers of AD pathology or precuneus volume.

Group comparison	Mean difference	SE	P _{uncorr} (1-tailed)	P _{corr} (1-tailed)	P-value rank (lowest to highest)
MCI>HC	1.61	,503	0.001*	0.005*	1
MCI>AD	2.17	,679	0.001*	0.004*	2
SCD>AD	1.42	,617	0.011*	0.033*	3
SCD>CON	.863	,415	0.020*	0.039*	4
AD <hc< td=""><td>562</td><td>,645</td><td>0.193</td><td>0.193</td><td>5</td></hc<>	562	,645	0.193	0.193	5

Table e-2. Group comparisons for precuneus activity differences in CSF sample


Post-hoc ttests in the subcohort of individuals with CSF data N=224 tested whether AD<HC<SCD/MCI (5 group comparisons). Group differences were mainly similar to the found pattern in the whole sample, with the only difference that activity in SCD was also higher than in the AD dementia group. Corrected p-values denote Bonferroni-Holm correction.

		Prec. Act.	Hipp. Act.	Entorhinal Act.	Postcentral Act.
N 4	D				
Memory	R	-,060	,116	,040	-,067
	P (2-tailed)	,191	,011	,381	,143
	df	479	479	479	479
MMSE	R	-,007	,097	,049	-,031
	P (2-tailed)	,876	,033	,282	,491
	df	480	480	480	480
Ав42/40	R	-,003	,104	,144	,028
	P (2-tailed)	,962	,124	,033	,679
	df	218	218	218	218
AB42/p-tau	R	,018	,153	,161	,029
	P (2-tailed)	,790	,023	,017	,664
	df	218	218	218	218
p-tau181	R	,010	-,102	-,112	-,041
	P (2-tailed)	,883	,132	,098	,544
	df	218	218	218	218
t-tau	R	-,048	-,162	-,155	-,051
	P (2-tailed)	,483	,016	,022	,451
	df	218	218	218	218
Precuneus Volume	R	-,002	-,004	-,100	,012
	P (2-tailed)	,963	,938	,027	,796
	df	480	480	480	480
Hipp. Volume	R	-,052	,031	-,001	-,051
	P (2-tailed)	,257	,497	,975	,260
	df	480	480	480	480
Entorhinal Volume	R	-,035	,031	,007	-,013
	P (2-tailed)	,450	,495	,871	,784
	df	480	480	480	480

Table e-3. Partial correlations of ROI novelty activity with cognition, CSF markers and volume

Partial Pearson correlations were run in the whole cohort (after excluding outliers with extreme values in activation, N=486), covarying for age, sex, education and site ID. Volumes are adjusted for intracranial volume. Significant correlations at p<0.05 uncorrected are highlighted in bold.

e-Figures



B. Activation by Memory groups and A-biomarker status (excluding AD dementia)





Figure e-1. Regional activation in clinical groups by A- and T-biomarker status and by high vs. **Iow memory groups.** (A) Activation by A+/A- and by T+/T- (B) Activation in predementia (HC/SCD/MCI) cases divided in low vs high memory groups by median split (Median = 0.387, including all subjects with memory performance) by A-biomarker group. NN: subject without CSF samples. N(Memory High)= 233, N(Memory Iow)= 234; N(CSF)=211: N(Mem Iow/A-)=71, N(Mem Iow/A+)=38, N(Mem high/A-)=83, N(Mem high/A+)=11,





A. Activation in hippocampus follows a nonlinear (quadratic) relationship with $A\beta 42/40$ levels. The $A\beta 42/40$ levels were inverted (*-1) to represent increased AD burden for display purposes.

B. Mean fMRI novelty-related activity in entorhinal cortex, hippocampus and precuneus across ATbiomarker defined groups based on CSF A β 42/40 and p-tau CSF concentrations. N(CSF)=224: N(A-T-)=122, N(A+T-)=10, N(A+T+)=59, N(A-T+)=33

e-Methods

Delcode study participants and sample selection

DELCODE is an observational longitudinal memory clinic based multicenter study in Germany, focusing on SCD in the context of AD, carried out by ten university-based memory clinics collaborating with local sites of the DZNE. Details about the sample, data acquisition, handling, and quality control have been previously in Jessen et al., 2018¹. As decribed in [1], the study includes individuals with MCI and mild AD as well as control subjects without subjective or objective cognitive impairment. In addition, a subgroup of first-degree relatives of patients with AD dementia were enrolled as an exploratory group at-risk for development of AD. All patient groups (SCD, MCI, AD) are referrals, including self-referrals, to the participating memory centers and were assessed clinically at the respective memory centers before entering DELCODE. The assessments include medical history, psychiatric and neurological examination, neuropsychological testing (as described below), blood sampling, and routine MRI scanning. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological test battery was applied at all memory centers to assess cognitive function. German age, sex, and education-adjusted norms of the CERAD neuropsychological battery are available online (www.memoryclinic.ch).


All subjects assigned to the SCD group had to report a subjectively perceived cognitive performance decline within at least the last 6 months and at most the last 5 years in a Personal Interview. In addition, they had to have average performance (<1.5 SD) in all subcategories of the CERAD-Plus administered for screening. Subjects were assigned to the MCI group if their performance on the CERAD was worse than average (>1.5 SD) on the "recall word list" subtest, they reported decreased cognitive performance, and at the same time they did not meet dementia criteria. By selecting a memory-related subtest, primarily amnestic MCI patients were included in the study. Patients with mild AD dementia² and >=18 points on the Mini Mental State Examination (MMSE) were included in DELCODE. SCD and amnestic MCI groups fulfill the current research criteria for SCD ^{3,4} or MCI⁵, respectively.

The control group and the group of first-degree relatives of AD patients were recruited by identical local newspaper advertisements. In the advertisement text, individuals were explicitly sought who felt healthy and without relevant cognitive problems. All individuals who responded to the advertisement were screened by telephone with regard to SCD. The report of very subtle cognitive decline, which did not cause any concerns and was considered normal for age by the individual, was not an exclusion criterion for the control group. For the first-degree relatives of AD, the advertisement did not exclude those with concerns of cognitive decline. AD in the relative (parent or sibling) had to be documented by medical records. Both the control group and the group of first-degree relatives had to achieve unimpaired cognitive performance according to the same definition as the SCD group.

Additional inclusion criteria for all groups were age \geq 60 years, fluent German language skills, capacity to provide informed consent, and presence of a study partner. The following medical conditions were considered exclusion criteria: current major depressive episode, major psychiatric disorders either at baseline or in the past (e.g., psychotic disorder, bipolar disorder, substance abuse), neurodegenerative disorder other than AD, vascular dementia, history of stroke with residual clinical symptoms, history of malignant disease, severe or unstable medical condition, and clinically significant abnormalities in vitamin B12. Prohibited drugs included chronic use of psychoactive compounds with sedative or anticholinergic effects, use of anti-dementia agents in SCD, amnestic MCI, and control subjects and in healthy siblings, and investigational drugs for treatment of dementia or cognitive impairment 1 month prior to entry and for the duration of the study.

As shown in the flowchart below, we included all subjects with complete fMRI task data and related logfiles, structural T1-MRI and cognitive data, excluding subjects with QA status "unusable". We next excluded the AD relatives, which is an exploratory at-risk group, as we had no hypothesis for this group (they could be expected to show similar activity as the HC group or might show mildly increased activity). Finally, for our ROI analyses, we excluded subjects that showed extreme activity values in at least one of the 4 ROIs using SPSS 24 (IBM, Armonk, NY) based on the interquartile range (IQR) (x > 75% percentile + 3 IQR; x < 25% percentile – 3 IQR). This led to the

exclusion of 13 subjects (4 HC, 5 SCD, and 4 MCI), leaving 486 subjects for ROIbased analyses of whom 224 had CSF data (122 A-T-, 10 A+T-, 59 A+T+, 33 A-T+).



Neuropsychological testing

The test battery included the Mini Mental State Examination (MMSE), ADAScog 13, the Free and Cued Selective Reminding Test, Wechsler Memory Scale revised version (WMS-R) Logical Memory Story A, WMS-R Digit Span, semantic fluency task, the oral form of the Symbol–Digit–Modalities Test (including subsequent free recall of symbols and symbol–digit pairings), Trail Making Test A and B, Clock Drawing, and Clock Copying. In addition to these established tests, two newly developed computerized tests were implemented: the Face Name Associative Recognition Test, and a Flanker task to assess executive control of attention. The cognitive testing was performed by a trained neuropsychologist at all sites.

As described in detail in [6] the memory factor score used in the current study was originally derived by a confirmatory factor analysis (CFA) applied to the DELCODEneuropsychological testing data at baseline. The CFA derived five cognitive domain scores: Learning & memory, language ability, executive functions and mental processing speed, working memory and visuo-spatial abilities (see Figure e-1 in ref. 6)

MRI and fMRI data acquisition

MRI data were acquired with Siemens scanners (3 TIM Trio systems, 4 Verio systems, one Skyra and one Prisma system) at 10 different scanning sites. The current analysis was performed using T1-weighted (3D GRAPPA PAT 2, 1mm3 isotropic, 256x256px, 192 slices, sagittal, ~5min, TR 2500ms, TE 4.33ms, TI 110ms, FA 7°) and a task-fMRI protocol (2D EPI, GRAPPA PAT 2, 3.5mm3 isotropic, 64x64px, 47 slices, oblique axial/AC-PC aligned, ~9 min, TR 2580ms, TE 30ms, FA 80°, 206 volumes). For more details see [1,7]. SOPs, quality assurance and assessment were provided and supervised by the DZNE imaging network¹.

References

1. Jessen F, Spottke A, Boecker H, et al. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). Alzheimers Res Ther [online serial]. 2018;10. Accessed at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802096/. Accessed October 25, 2020.

2. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–269.

3. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014;10:844–852.

4. Molinuevo JL, Rabin LA, Amariglio R, et al. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017;13:296–311.

5. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270–279.

6. Wolfsgruber S, Kleineidam L, Guski J, et al. Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology. 2020;95:e1134–e1143.

7. Düzel E, Berron D, Schütze H, et al. CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring [online serial]. Epub 2018 Nov 2. Accessed at: http://www.sciencedirect.com/science/article/pii/S235287291830071X. Accessed November 17, 2018.

e-Results

Spearman rank correlation between clinical group and activity

Spearman rank correlation between groups and novelty-related activity in each ROI were calculated and p-values were corrected for the number of analyses (alpha=0.05, 4 ROIs; corrected p-threshold_{1-tailed} < 0.0125). Spearman rank correlations between the clinical group, ranked by expected activity increases (1=AD, 2=HC, 3=SCD/MCI). and activity in the different ROIs revealed a significant positive association in precuneus (rho =.130; $p_{1-tailed}$ = 0.002, p_{corr} =0.008) surviving correction for multiple comparisons. There was a similar but weaker association for hippocampus (rho =.098; $p_{1-tailed}$ = 0.016, p_{corr} =0.064) not surviving correction for multiple comparisons. Correlations for ERC (rho =.066; $p_{1-tailed}$ = 0.074, p_{corr} =0.296) and postcentral gyrus (rho =.065; $p_{1-tailed}$ = 0.078, p_{corr} = 0.312) were not significant.